Northpointe Capital’s Novavax NVAX Stock Holding History

Northpointe Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-83,345	Closed	-$3.47M	–	201
2016 Q3	$3.47M	Sell	83,345 -22,857	-22%	-$2.95M	0.36%	109
2016 Q2	$15.4M	Buy	106,202 +34,057	+47%	+$3.9M	1.82%	3
2016 Q1	$7.45M	Buy	72,145 +46,778	+184%	+$5.02M	0.92%	29
2015 Q4	$3.59M	Hold	25,367	–	–	0.47%	74
2015 Q3	$3.59M	Sell	25,367 -14,191	-36%	-$3.18M	0.47%	75
2015 Q2	$8.81M	Sell	39,558 -26,039	-40%	-$4.58M	1.04%	28
2015 Q1	$10.8M	Sell	65,597 -47,357	-42%	-$7.69M	1.17%	15
2014 Q4	$13.4M	Buy	112,954 +9,620	+9%	+$1.01M	1.61%	5
2014 Q3	$8.62M	Sell	103,334 -330	-0.3%	-$29.8K	0.91%	32
2014 Q2	$9.58M	Buy	103,664 +16,900	+19%	+$1.49M	0.92%	33
2014 Q1	$7.86M	Buy	+86,764	New	+$9.69M	0.8%	52

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QIM

Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Northpointe Capital's NVAX Position: Q4 2016 in Review

Northpointe Capital sold out of Novavax (NVAX) in Q4 2016, closing a stake of 83,345 shares — an estimated $3.47M sold.

Northpointe Capital first reported a position in NVAX in Q1 2014 and held it in 11 quarters. The position peaked at $15.4M in Q2 2016. 142 funds tracked by Wall St. Rank hold NVAX as of Q4 2016.

Northpointe Capital reported no remaining Novavax position as of Q4 2016 after selling out during the quarter.
Northpointe Capital sold 83,345 Novavax shares in Q4 2016, an estimated $3.47M.
Northpointe Capital first reported a position in Novavax in Q1 2014 and held it in 11 quarters.
Northpointe Capital's Novavax position peaked at $15.4M in Q2 2016.
142 funds tracked by Wall St. Rank held Novavax as of Q4 2016.

Based on Northpointe Capital's 13F filing for Q4 2016, filed 25 Jan 2017.